ERcast: Clinical Perspectives Podcast Preview

Subscription Required

Swollen Airways & Sickled Cells

Anne Steckowych, APRN, Brett Murray, MD, Jeremy Driscoll, MD, Brit Long, MD, and Julie Kanter, MD

Sign in or Subscribe to listen.
5 starson Spotify
Sign in or Subscribe to view.Sign in or Subscribe to view.

The summary below is from an episode of ERcast: Clinical Perspectives

Angioedema can kill by airway obstruction, and the first branch point is histamine versus bradykinin because the treatments diverge early. Sickle cell disease is not just a pain-crisis diagnosis; hypoxia, hemolysis, and falling platelets are the bedside clues to organ-threatening complications.

Angioedema airway and treatment decisions

  • Airway-first mortality risk: Airway compromise is the leading cause of death in angioedema, so voice change, drooling, tongue swelling, and inability to lie flat should push immediate reassessment.
  • Histamine versus bradykinin: Urticaria and pruritus point toward histamine-mediated disease, while slower swelling without hives suggests bradykinin-mediated angioedema that often ignores standard allergy therapy.
  • Difficult airway strategy: When the airway is threatened, awake intubation is preferred when feasible and every attempt needs a double setup because surgical airway is common in true crashes, a practical setup we walk through in the episode.
  • Targeted bradykinin therapy: C1 esterase inhibitor replacement is the named first-line therapy for hereditary bradykinin angioedema, while ACE-inhibitor cases have more mixed evidence for targeted agents.
  • Low-yield ED testing: C4, C1 inhibitor, and tryptase testing rarely changes emergency management, and CT or plain films should not decide airway safety when direct airway assessment is available.
  • Adjuncts and disposition: Tranexamic acid has limited but promising support as a low-cost adjunct, while any tongue, soft palate, or posterior pharyngeal involvement should usually mean ICU-level observation.

Sickle cell emergencies beyond pain

  • Pain with danger scan: Treat sickle cell pain as an acute pain crisis unless proven otherwise, but do not let analgesia distract from acute chest syndrome, stroke, splenic sequestration, or severe anemia.
  • Core laboratory signals: CBC, CMP, LDH, reticulocyte count, and urinalysis are the key initial studies; reticulocytes show marrow response and transfusion context, not whether the patient is truly in crisis.
  • Red flags for admission: Hypoxia, tachycardia out of proportion, platelets under 150, and LDH above 1000 are warning signs for deterioration and should lower the threshold for specialist involvement.
  • Acute chest recognition: Acute chest syndrome is vaso-occlusion in the lungs and a leading cause of death; chest x-ray can mimic pneumonia, while diffuse ground-glass on CT makes acute chest less likely.
  • Stroke means exchange: A focal neurologic deficit in a patient with sickle cell disease should be treated as sickle-related stroke until proven otherwise, with exchange transfusion prioritized early. We get into the imaging and line-timing nuances in the chapter.
  • Analgesia and fluids: Opioids are first-line and often need repeat dosing every 30 minutes early, while routine large-volume normal saline is a poor default in uncomplicated pain crises.

Subscribe to ERcast: Clinical Perspectives to listen to the episode.

References:

  1. Long B, Rech MA, Gottlieb M. Managing Angioedema. Ann Emerg Med. 2025 Aug 14:S0196-0644(25)01046-7.  Epub ahead of print. PMID: 40810708.

Faculty